FDA Recall D-0182-2025

FDC Limited

Class II Ongoing 514 days on record

Moderate impact — Class II recall — temporary or medically reversible adverse health consequence possible; remote probability of serious adverse health consequence.

Product

Ciprofloxacin Ophthalmic Solution USP, 0.3% as base, Sterile, package in 5 mL bottles, Rx Only, Distributed by: Leading Pharma LLC, Fairfield, NJ. Manufactured by: FDC Limited, Maharashtra, India, NDC 69315-308-05

Lot / code: Lot: 083L111, Exp. 11/30/2025; 084A032, Exp. 12/31/2025

Quantity: 136,181 bottles

Reason for recall

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Recall record

Recall number: D-0182-2025
Classification: Class II
Status: Ongoing
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Letter
Distribution: Nationwide
Recall initiated: 2024-12-16
Classified by FDA Center: 2025-01-03
FDA published: 2025-01-15
Recalling firm: FDC Limited

Drug identification

Brand name(s): CIPROFLOXACIN
Generic name(s): CIPROFLOXACIN
Manufacturer(s): Leading Pharma, LLC
NDC(s): 69315-308
Route(s): OPHTHALMIC

Operational response

Class II recalls indicate possible temporary or reversible health consequences. Remove affected lots from active dispensing. Segregate inventory. Check the firm’s recall notification for guidance on patient outreach.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls